title: Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Charokopou
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: H
authors.initials: H
authors.lastname: Vioix
authors.affiliation: Costello Medical Consulting Ltd., Cambridge, UK.
authors.forename: L A
authors.initials: LA
authors.lastname: Eddowes
authors.affiliation: Costello Medical Consulting Ltd., Cambridge, UK.
authors.forename: M
authors.initials: M
authors.lastname: Griffiths
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B G
authors.initials: BG
authors.lastname: Verheggen
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: Z
authors.initials: Z
authors.lastname: Gabriel
authors.affiliation: Tolley Health Economics Ltd., Buxton, Derbyshire, UK.
authors.forename: K
authors.initials: K
authors.lastname: Tolley